Salama Ibrahim A, Korayem Enas, ElAbd Osama, El-Refaie Ahmed
Department of Surgery, National Liver Institute, Menouphyia University, Shebin El Kom, Egypt.
J Laparoendosc Adv Surg Tech A. 2010 Feb;20(1):39-46. doi: 10.1089/lap.2009.0208.
The optimal treatment for hepatocellular carcinoma (HCC) is surgical resection. However, only a small percentage of patients are operative candidates due to associated liver cirrhosis. Recent advances in laparoscopic ultrasound and laparoscopy have greatly improved the accuracy in detecting intrahepatic tumor nodules, many of which were missed by preoperative imaging modality.
The aim of this work was for an evaluation of the safety and efficacy of laparoscopic radiofrequency ablation (RFA) guided with laparoscopic ultrasound in detecting and treatment of liver tumors in patient with liver cirrhosis.
Seventy-two patients with liver tumors (58 HCC, 9 metastatic adencarcinoma, 2 neoendocrine metastasis, 3 other metastasis) were submitted to laparoscopic RFA under laparoscopic ultrasound guidance. Forty-four patients (61.1%) were classified Child A and 28 patients (38.9%) Child B. Patients with large tumor (>6 cm), portal vein thrombosis, or Child C class were excluded from the study.
Laparoscopic RFA was completed in all patients without any conversion rate. Laparoscopic ultrasound identified 19 new malignant lesions (18.4%), in comparison with the result of preoperative imaging. A total of 103 hepatic focal lesions were treated by RFA (45 patients had 1 lesion, 23 patients had 2 lesions, and 4 patients had 3 lesions). There was no mortality. Morbidity occurred in 4 patients (5.5%): 2 patients had liver abscesses, 1 patient had pleural effusion, and 1 patient had postoperative bleeding necessitating blood transfusion and surgery. After a mean follow-up of 14.3 +/- 11.6 months, a complete response with 100% necrosis was achieved in 93 of 103 lesions (90.3%). Three lesions (2.9%) showed local recurrences, 5 lesions (4.8%) showed remote recurrences, and 2 lesions (1.9%) showed both local and remote recurrences.
Laparoscopic RFA guided with laparoscopic ultrasound is an excellent use of existing technology in the improvement of safety and efficacy of detection and treatment of intrahepatic tumors in patients with liver cirrhosis.
肝细胞癌(HCC)的最佳治疗方法是手术切除。然而,由于合并肝硬化,只有一小部分患者适合手术。腹腔镜超声和腹腔镜技术的最新进展极大地提高了肝内肿瘤结节的检测准确性,许多结节术前影像学检查未能发现。
本研究旨在评估腹腔镜超声引导下腹腔镜射频消融(RFA)治疗肝硬化患者肝肿瘤的安全性和有效性。
72例肝肿瘤患者(58例HCC、9例转移性腺癌、2例神经内分泌转移瘤、3例其他转移瘤)在腹腔镜超声引导下接受腹腔镜RFA治疗。44例(61.1%)患者为Child A级,28例(38.9%)为Child B级。肿瘤较大(>6 cm)、门静脉血栓形成或Child C级患者被排除在研究之外。
所有患者均成功完成腹腔镜RFA,无中转开腹病例。与术前影像学检查结果相比,腹腔镜超声发现19个新的恶性病变(18.4%)。共对103个肝局灶性病变进行了RFA治疗(45例患者有1个病变,23例患者有2个病变,4例患者有3个病变)。无死亡病例。4例患者(5.5%)出现并发症:2例患者发生肝脓肿,1例患者出现胸腔积液,1例患者术后出血,需输血及手术治疗。平均随访14.3±11.6个月后,103个病变中的93个(90.3%)实现了100%坏死的完全缓解。3个病变(2.9%)出现局部复发,5个病变(4.8%)出现远处复发,2个病变(1.9%)同时出现局部和远处复发。
腹腔镜超声引导下的腹腔镜RFA是利用现有技术提高肝硬化患者肝内肿瘤检测和治疗安全性及有效性的一种优秀方法。